Otter Creek Advisors LLC Sells 258 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Otter Creek Advisors LLC trimmed its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 17.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,196 shares of the medical research company’s stock after selling 258 shares during the quarter. Otter Creek Advisors LLC’s holdings in IQVIA were worth $235,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. Smith Group Asset Management LLC bought a new stake in IQVIA in the 4th quarter worth about $1,616,000. Simplify Asset Management Inc. boosted its holdings in IQVIA by 67.8% in the third quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock worth $2,284,000 after purchasing an additional 3,894 shares during the last quarter. Nordea Investment Management AB grew its position in IQVIA by 47.4% in the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after purchasing an additional 452,029 shares during the period. Hickory Asset Management Inc. purchased a new stake in IQVIA during the 4th quarter valued at $941,000. Finally, Fifth Third Bancorp lifted its holdings in shares of IQVIA by 13.0% during the 4th quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company’s stock valued at $2,590,000 after buying an additional 1,521 shares during the period. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Price Performance

IQVIA stock opened at $190.77 on Thursday. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The firm has a 50-day moving average price of $199.40 and a 200-day moving average price of $215.46. IQVIA Holdings Inc. has a 12-month low of $187.62 and a 12-month high of $261.73. The firm has a market capitalization of $33.59 billion, a PE ratio of 25.44, a price-to-earnings-growth ratio of 1.99 and a beta of 1.48.

IQVIA (NYSE:IQV) last issued its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analysts Set New Price Targets

IQV has been the subject of a number of research reports. StockNews.com cut IQVIA from a “buy” rating to a “hold” rating in a research report on Thursday, November 28th. Leerink Partners reaffirmed an “outperform” rating and set a $248.00 price target (down previously from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. Barclays dropped their price objective on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a report on Monday, February 3rd. Deutsche Bank Aktiengesellschaft reduced their target price on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a report on Friday, November 1st. Finally, Robert W. Baird dropped their price target on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 21st. Four equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $251.22.

Insider Buying and Selling at IQVIA

In related news, Director John G. Danhakl bought 1,275 shares of the stock in a transaction on Tuesday, December 3rd. The stock was bought at an average price of $200.58 per share, for a total transaction of $255,739.50. Following the completion of the acquisition, the director now directly owns 1,275 shares in the company, valued at approximately $255,739.50. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 1.60% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.